Richardson, P., McKenna, W., Bristow, M., Maisch, B., Mautner, B., O’Connell, J., Olsen, E., Thiene, G., Good- win, J., Gyarfas, I., Martin, I. and Nordet, P. (1996) Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the definition and classification of cardiomyopathies. Circulation, 93, 841-842. doi:10.1161/01.CIR.93.5.841

has been cited by the following article:

• TITLE: Immunoadsorption therapy reduces oxidative stress in patients with dilated cardiomyopathy

  AUTHORS: Hiroki Kasai, Yuichiro Kashima, Atsushi Izawa, Takeshi Tomita, Yusuke Miyashita, Jun Koyama, Masafumi Takahashi, Taku Yoshio, Yoshikazu Yazaki, Makoto Higuchi, Uichi Ikeda

  KEYWORDS: Autoantibody; Immunoglobulin; Plasmapheresis

  JOURNAL NAME: World Journal of Cardiovascular Diseases, Vol.2 No.4, October 30, 2012

  ABSTRACT: Several literatures have reported that the elimination of autoantibodies by immunoadsorption (IA) therapy induced short- and long-term improvements in cardiac function of patients with dilated cardiomyopathy (DCM). We assessed whether reduction in oxidative stress was related to the mechanism underlying left ventricular functional benefit from IA. We studied 7 patients with DCM (New York Heart Association (NYHA) functional class III/IV). Autoantibodies were removed with IA by passing patients’ plasma over tryptophan columns. The level of anti-β1-adrenoreceptor (AR) autoantibodies was measured by enzyme- linked immunosorbent assay. The level of diacron- reactive oxygen metabolite (d-ROM) was determined as a marker of oxidative stress. During IA, the anti- β1-AR autoantibodies titers of all the patients decreased significantly from 27.8 ± 5.0 to 18.7 ± 5.5 U/ml (p